Publications

  1. Maroun J, Munoz-Alia M, Ammayappan A, Schulze A, Peng KW, Russell S. Designing and building oncolytic viruses Future Virology 2017; 12 (4):193-213
  2. Hickey RD, Mao SA, Glorioso J, Elgilani F, Amiot B, Chen H, Rinaldo P, Marler R, Jiang H, DeGrado TR, Suksanpaisan L, O'Connor MK, Freeman BL, Ibrahim SH, Peng KW, Harding CO, Ho CS, Grompe M, Ikeda Y, Lillegard JB, Russell SJ, Nyberg SL. Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1. Sci Transl Med 2016 Jul 27; 8 (349):349ra99
    View PubMed
  3. Shen W, Patnaik MM, Ruiz A, Russell SJ, Peng KW. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood 2016 Mar 17; 127 (11):1449-58 Epub 2015 Dec 28
    View PubMed
  4. Miller A, Nace R, Ayala-Breton C C, Steele M, Bailey K, Peng KW, Russell SJ. Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses. Mol Ther 2016 Feb; 24 (2):306-17 Epub 2015 Dec 09
    View PubMed
  5. Deyle DR, Escobar DZ, Peng KW, Babovic-Vuksanovic D. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors. Gene. 2015 Jul 1; 565(1):140-5. Epub 2015 Apr 02.
    View PubMed
  6. Holditch SJ, Schreiber CA, Nini R, Tonne JM, Peng KW, Geurts A, Jacob HJ, Burnett JC, Cataliotti A, Ikeda Y. B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human Hypertension. Hypertension 2015 Jul; 66 (1):199-210 Epub 2015 May 11
    View PubMed
  7. Hickey RD, Mao SA, Amiot B, Suksanpaisan L, Miller A, Nace R, Glorioso J, O'Connor MK, Peng KW, Ikeda Y, Russell SJ, Nyberg SL. Noninvasive 3-dimensional imaging of liver regeneration in a mouse model of hereditary tyrosinemia type 1 using the sodium iodide symporter gene. Liver Transpl 2015 Apr; 21 (4):442-53 Epub 2015 Mar 12
    View PubMed
  8. Tesfay MZ, Kirk AC, Hadac EM, Griesmann GE, Federspiel MJ, Barber GN, Henry SM, Peng KW, Russell SJ. Erratum for Tesfay et al., PEGylation of Vesicular Stomatitis Virus Extends Virus Persistence in Blood Circulation of Passively Immunized Mice. J Virol. 2015 Feb 15; 89(4):2453.
    View PubMed
  9. Tesfay MZ, Ammayappan A, Federspiel MJ, Barber GN, Stojdl D, Peng KW, Russell SJ. Correction for Tesfay et al., Vesiculovirus Neutralization by Natural IgM and Complement. J Virol. 2015 Feb 1; 89(3):1945-6.
    View PubMed
  10. Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res 2015 Jan 01; 75 (1):22-30 Epub 2014 Nov 14
    View PubMed
  11. Kurisetty VVS, Heiber J, Myers R, Pereira GS, Goodwin JW, Federspiel MJ, Russell SJ, Peng KW, Barber G, Merchan JR. Preclinical safety and activity of recombinant vsv-ifn-beta in an immunocompetent model of squamous cell carcinoma of the head and neck. Head Neck. 2014 Nov; 36(11):1619-27.
    View PubMed
  12. Ayala-Breton C, Russell LO, Russell SJ, Peng KW. Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus. J Virol 2014 Aug; 88 (15):8332-9 Epub 2014 May 14
    View PubMed
  13. Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, Lowe V, O'Connor MK, Kyle RA, Leung N, Buadi FK, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc 2014 Jul; 89 (7):926-33 Epub 2014 May 14
    View PubMed
  14. Tesfay MZ, Ammayappan A, Federspiel MJ, Barber GN, Stojdl D, Peng KW, Russell SJ. Vesiculovirus neutralization by natural IgM and complement. J Virol 2014 Jun; 88 (11):6148-57 Epub 2014 Mar 19
    View PubMed
  15. Suksanpaisan L, Russell SJ, Peng KW. High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus. Cancer Gene Ther 2014 Jun; 21 (6):256-60 Epub 2014 May 30
    View PubMed
  16. Liu YP, Wang J, Avanzato VA, Bakkum-Gamez JN, Russell SJ, Bell JC, Peng KW. Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol Oncol 2014 Mar; 132 (3):722-9 Epub 2014 Jan 14
    View PubMed
  17. Liu YP, Russell SP, Ayala-Breton C, Russell SP, Peng KW. Ablation of nectin4 binding compromises CD46 usage by a hybrid vesicular stomatitis virus/measles virus. J Virol 2014 Feb; 88 (4):2195-204 Epub 2013 Dec 11
    View PubMed
  18. Liu YP, Steele MB, Suksanpaisan L, Federspiel MJ, Russell SJ, Peng KW, Bakkum-Gamez JN. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer. Gynecol Oncol 2014 Jan; 132 (1):194-202 Epub 2013 Nov 15
    View PubMed
  19. Ammayappan A, Peng KW, Russell SJ. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands. J Virol 2013 Dec; 87 (24):13543-55 Epub 2013 Oct 02
    View PubMed
  20. LeBlanc AK, Naik S, Galyon GD, Jenks N, Steele M, Peng KW, Federspiel MJ, Donnell R, Russell SJ. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. Human Gene Therapy Clinical Development. 2013 Dec; 24(4):174-81.
    View PubMed
  21. Suksanpaisan L, Pham L, McIvor S, Russell SJ, Peng KW. Oral contrast enhances the resolution of in-life NIS reporter gene imaging. Cancer Gene Ther 2013 Nov; 20 (11):638-41 Epub 2013 Sept 13
    View PubMed
  22. Yarde DN, Naik S, Nace RA, Peng KW, Federspiel MJ, Russell SJ. Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV. Cancer Gene Ther 2013 Nov; 20 (11):616-21 Epub 2013 Nov 01
    View PubMed
  23. Ong HT, Federspiel MJ, Guo CM, Ooi LL, Russell SJ, Peng KW, Hui KM. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol. 2013 Nov; 59(5):999-1006. Epub 2013 Jul 16.
    View PubMed
  24. Ayala-Breton C, Suksanpaisan L, Mader EK, Russell SJ, Peng KW. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread. Mol Ther 2013 Oct; 21 (10):1930-7 Epub 2013 July 11
    View PubMed
  25. Escobar-Zarate D, Liu YP, Suksanpaisan L, Russell SJ, Peng KW. Overcoming cancer cell resistance to VSV oncolysis with JAK12 inhibitors. Cancer Gene Ther 2013 Oct; 20 (10):582-9 Epub 2013 Sept 13
    View PubMed
  26. Liu C, Suksanpaisan L, Chen YW, Russell SJ, Peng KW. Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp Hematol 2013 Jun; 41 (6):508-17 Epub 2013 Feb 08
    View PubMed
  27. Tesfay MZ, Kirk AC, Hadac EM, Griesmann GE, Federspiel MJ, Barber GN, Henry SM, Peng KW, Russell SJ. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. J Virol 2013 Apr; 87 (7):3752-9 Epub 2013 Jan 16
    View PubMed
  28. Friedrich K, Hanauer JR, Prufer S, Munch RC, Volker I, Filippis C, Jost C, Hanschmann KM, Cattaneo R, Peng KW, Pluckthun A, Buchholz CJ, Cichutek K, Muhlebach MD. DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther. 2013 Apr; 21(4):849-59. Epub 2013 Feb 05.
    View PubMed
  29. Peng KW, Myers R, Greenslade A, Mader E, Greiner S, Federspiel MJ, Dispenzieri A, Russell SJ. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther 2013 Mar; 20 (3):255-61 Epub 2012 Apr 05
    View PubMed
  30. Ammayappan A, Nace R, Peng KW, Russell SJ. Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites. J Virol 2013 Mar; 87 (6):3217-28 Epub 2013 Jan 02
    View PubMed
  31. Lam P, Khan G, Stripecke R, Hui KM, Kasahara N, Peng KW, Guinn BA. The innovative evolution of cancer gene and cellular therapies. Cancer Gene Ther. 2013 Mar; 20(3):141-9. Epub 2013 Feb 01.
    View PubMed
  32. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB, Peng KW. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med 2013 Jan 24; 11:20
    View PubMed
  33. Liu YP, Suksanpaisan L, Steele MB, Russell SJ, Peng KW. Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy. Sci Rep 2013; 3:2375
    View PubMed
  34. Bailey K, Kirk A, Naik S, Nace R, Steele MB, Suksanpaisan L, Li X, Federspiel MJ, Peng KW, Kirk D, Russell SJ. Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters. PLoS One 2013; 8 (9):e73759 Epub 2013 Sept 11
    View PubMed
  35. Reddi HV, Madde P, McDonough SJ, Trujillo MA, Morris JC, Myers RM, Peng KW, Russell SJ, McIver B, Eberhardt NL. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther 2012 Sep; 19 (9):659-65 Epub 2012 July 13
    View PubMed
  36. Naik S, Nace R, Federspiel MJ, Barber GN, Peng KW, Russell SJ. Curative one-shot systemic virotherapy in murine myeloma. Leukemia 2012 Aug; 26 (8):1870-8 Epub 2012 Mar 19
    View PubMed
  37. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012 Jul 10; 30 (7):658-70 Epub 2012 July 10
    View PubMed
  38. Iankov ID, Allen C, Federspiel MJ, Myers RM, Peng KW, Ingle JN, Russell SJ, Galanis E. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. Mol Ther 2012 Jun; 20 (6):1139-47 Epub 2012 Feb 14
    View PubMed
  39. Ayala-Breton C, Barber GN, Russell SJ, Peng KW. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther 2012 May; 23 (5):484-91 Epub 2012 Feb 07
    View PubMed
  40. Liu YP, Tong C, Dispenzieri A, Federspiel MJ, Russell SJ, Peng KW. Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. Cancer Gene Ther 2012 Mar; 19 (3):202-11 Epub 2011 Nov 25
    View PubMed
  41. Li H, Peng KW, Russell SJ. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy. Hum Gene Ther 2012 Mar; 23 (3):295-301 Epub 2012 Jan 11
    View PubMed
  42. Sakuma T, Tonne JM, Malcolm JA, Thatava T, Ohmine S, Peng KW, Ikeda Y. Long-term infection and vertical transmission of a gammaretrovirus in a foreign host species. PLoS One 2012; 7 (1):e29682 Epub 2012 Jan 03
    View PubMed
  43. Cataliotti A, Tonne JM, Bellavia D, Martin FL, Oehler EA, Harders GE, Campbell JM, Peng KW, Russell SJ, Malatino LS, Burnett JC Jr, Ikeda Y. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation 2011 Mar 29; 123 (12):1297-305 Epub 2011 Mar 14
    View PubMed
  44. Sakuma T, Tonne JM, Squillace KA, Ohmine S, Thatava T, Peng KW, Barry MA, Ikeda Y. Early events in retrovirus XMRV infection of the wild-derived mouse Mus pahari. J Virol 2011 Feb; 85 (3):1205-13 Epub 2010 Nov 17
    View PubMed
  45. Ennis MK, Hu C, Naik SK, Hallak LK, Peng KW, Russell SJ, Dingli D. Mutations in the stalk region of the measles virus hemagglutinin inhibit syncytium formation but not virus entry. J Virol 2010 Oct; 84 (20):10913-7 Epub 2010 Aug 11
    View PubMed
  46. Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 2010 Aug; 17 (8):550-8 Epub 2010 Apr 09
    View PubMed
  47. Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 2010 Jun; 18 (6):1155-64 Epub 2010 Mar 16
    View PubMed
  48. Jenks N, Myers R, Greiner SM, Thompson J, Mader EK, Greenslade A, Griesmann GE, Federspiel MJ, Rakela J, Borad MJ, Vile RG, Barber GN, Meier TR, Blanco MC, Carlson SK, Russell SJ, Peng KW. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther 2010 Apr; 21 (4):451-62
    View PubMed
  49. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010 Feb 01; 70 (3):875-82 Epub 2010 Jan 26
    View PubMed
  50. Guinn B, Casey G, Moller MG, Kasahara N, O'Sullivan GC, Peng KW, Tangney M. International Society for Cell and Gene Therapy of Cancer 2009 Annual Meeting held in Cork, Ireland. Hum Gene Ther. 2010 Jan; 21(1):9-26.
    View PubMed
  51. Dingli D, Offord C, Myers R, Peng KW, Carr TW, Josic K, Russell SJ, Bajzer Z. Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. Cancer Gene Ther 2009 Dec; 16 (12):873-82 Epub 2009 June 05
    View PubMed
  52. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB, Peng KW. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009 Dec 01; 15 (23):7246-55 Epub 2009 Nov 24
    View PubMed
  53. Frecha C, Costa C, Levy C, Negre D, Russell SJ, Maisner A, Salles G, Peng KW, Cosset FL, Verhoeyen E. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood. 2009 Oct 8; 114(15):3173-80. Epub 2009 Aug 10.
    View PubMed
  54. Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 2009 Jul 01; 69 (10):1128-41
    View PubMed
  55. Peng KW, Dogan A, Vrana J, Liu C, Ong HT, Kumar S, Dispenzieri A, Dietz AB, Russell SJ. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol 2009 Jul; 84 (7):401-7
    View PubMed
  56. Ong HT, Trejo TR, Pham LD, Oberg AL, Russell SJ, Peng KW. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol Ther 2009 Jun; 17 (6):1012-21 Epub 2009 Mar 10
    View PubMed
  57. Pham L, Nakamura T, Gabriela Rosales A, Carlson SK, Bailey KR, Peng KW, Russell SJ. Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome. J Gene Med 2009 Mar; 11 (3):197-206
    View PubMed
  58. Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009; 330:213-41
    View PubMed
  59. Wang H, Liu Y, Li Z, Tuve S, Stone D, Kalyushniy O, Shayakhmetov D, Verlinde CL, Stehle T, McVey J, Baker A, Peng KW, Roffler S, Lieber A. In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. J Virol. 2008 Nov; 82(21):10567-79. Epub 2008 Aug 27.
    View PubMed
  60. Han YJ, Loo SC, Phung NT, Ong HT, Russell SJ, Peng KW, Boey F, Ma J. Controlled size and morphology of EDTMP-doped hydroxyapatite nanoparticles as model for 153Samarium-EDTMP doping. J Mater Sci Mater Med. 2008 Sep; 19(9):2993-3003. Epub 2008 Mar 25.
    View PubMed
  61. Russell SJ, Peng KW. The utility of cells as vehicles for oncolytic virus therapies. Curr Opin Mol Ther. 2008 Aug; 10(4):380-6.
    View PubMed
  62. Galanis E, Hartmann LC, Cliby W, Peethambaram PP, Long HJ, Kaur JS, Haluska P Jr, Sloan JA, Peng K, Russell SJ. Phase I trial of Intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa). J Clin Oncol 2008 May 20; 26 (15_suppl):5538
    View PubMed
  63. Ong HT, Loo JSC, Boey FYC, Russell SJ, Ma J, Peng KW. Exploiting the high-affinity phosphonate-hydroxyapatite nanoparticle interaction for delivery of radiation and drugs. Journal of Nanoparticle Research. 2008 Feb; 10(1):141-50.
    View PubMed
  64. Allen C, Paraskevakou G, Liu C, Iankov ID, Msaouel P, Zollman P, Myers R, Peng KW, Russell SJ, Galanis E. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 2008 Feb; 8 (2):213-20
    View PubMed
  65. Chang M, Overk CR, Kastrati I, Peng KW, Yao P, Qin ZH, Petukhov P, Bolton JL, Thatcher GR. Estrogenic activity of the equine estrogen metabolite, 4-methoxyequilenin. Adv Exp Med Biol. 2008; 617:601-7.
    View PubMed
  66. Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ, Peng KW. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol 2007 Dec; 81 (23):13149-57 Epub 2007 Sept 05
    View PubMed
  67. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA, Reid JM, Federspiel M, Ames MM, Dingli D, Schweikart K, Welch A, Dispenzieri A, Peng KW, Russell SJ. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007 Dec; 82 (6):700-10 Epub 2007 Oct 31
    View PubMed
  68. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci 2007 Jul; 28 (7):326-33 Epub 2007 June 18
    View PubMed
  69. Paraskevakou G, Allen C, Nakamura T, Zollman P, James CD, Peng KW, Schroeder M, Russell SJ, Galanis E. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther 2007 Apr; 15 (4):677-86 Epub 2007 Feb 13
    View PubMed
  70. Haralambieva I, Iankov I, Hasegawa K, Harvey M, Russell SJ, Peng KW. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther 2007 Mar; 15 (3):588-97 Epub 2007 Jan 16
    View PubMed
  71. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 2007 Feb; 14(4):324-33. Epub 2006 Oct 19.
    View PubMed
  72. Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Peng KW, Goble JM, Uhm JH, Russell SJ, Galanis E. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res. 2006 Dec 15; 66(24):11840-50.
    View PubMed
  73. Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, Federspiel MJ, Russell SJ, LaRusso NF. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology. 2006 Dec; 44(6):1465-77.
    View PubMed
  74. Hasegawa K, Nakamura T, Harvey M, Ikeda Y, Oberg A, Figini M, Canevari S, Hartmann LC, Peng KW. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):6170-8.
    View PubMed
  75. Peng KW, Hadac EM, Anderson BD, Myers R, Harvey M, Greiner SM, Soeffker D, Federspiel MJ, Russell SJ. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther. 2006 Aug; 13(8):732-8. Epub 2006 Mar 10.
    View PubMed
  76. Galanis E, Hartmann LC, Cliby W, Zollman PJ, Peethambaram PP, Long HJ, Kaur JS, Sloan JA, Peng KW, Russell SJ. Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in ovarian cancer patients. J Clin Oncol 2006 Jun 20; 24 (18_suppl):5028
    View PubMed
  77. Ong HT, Timm MM, Greipp PR, Witzig TE, Dispenzieri A, Russell SJ, Peng KW. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol. 2006 Jun; 34(6):713-20.
    View PubMed
  78. Goel A, Dispenzieri A, Geyer SM, Greiner S, Peng KW, Russell SJ. Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood 2006 May 15; 107 (10):4063-70 Epub 2006 Jan 19
    View PubMed
  79. Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res. 2006 Mar 15; 12(6):1868-75.
    View PubMed
  80. Hasegawa K, Peng KW. Oncolytic measles virus for ovarian cancer therapy. [Japanese]. Biotherapy. 2006; 20(6):549-56.
    View PubMed
  81. Dingli D, Peng KW, Harvey ME, Vongpunsawad S, Bergert ER, Kyle RA, Cattaneo R, Morris JC, Russell SJ. Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem Biophys Res Commun. 2005 Nov 11; 337(1):22-9.
    View PubMed
  82. Myers R, Greiner S, Harvey M, Soeffker D, Frenzke M, Abraham K, Shaw A, Rozenblatt S, Federspiel MJ, Russell SJ, Peng KW. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther. 2005 Jul; 12(7):593-9.
    View PubMed
  83. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IAJ, James CD, Russell SJ. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol. 2005 Feb; 23(2):209-14.
    View PubMed
  84. Kanerva A, Zinn KR, Peng KW, Ranki T, Kangasniemi L, Chaudhuri TR, Desmond RA, Wang M, Takayama K, Hakkarainen T, Alfthan H, Stenman UH, Curiel DT, Hemminki A. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther. 2005 Jan; 12(1):87-94.
    View PubMed
  85. Hadac EM, Peng KW, Nakamura T, Russell SJ. Reengineering paramyxovirus tropism. Virology 2004 Nov 24; 329 (2):217-25
    View PubMed
  86. Allen C, McDonald C, Giannini C, Peng KW, Rosales G, Russell SJ, Galanis E. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas. J Gene Med. 2004 Nov; 6(11):1216-27.
    View PubMed
  87. Peng KW, Holler PD, Orr BA, Kranz DM, Russell SJ. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor. Gene Ther. 2004 Aug; 11(15):1234-9.
    View PubMed
  88. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004 Jul 15; 64(14):4919-26.
    View PubMed
  89. Nakamura T, Peng KW, Vongpunsawad S, Harvey M, Mizuguchi H, Hayakawa T, Cattaneo R, Russell SJ. Antibody-targeted cell fusion. Nat Biotechnol 2004 Mar; 22 (3):331-6 Epub 2004 Feb 15
    View PubMed
  90. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, Morris JC, Russell SJ. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004 Mar 1; 103(5):1641-6. Epub 2003 Nov 06.
    View PubMed
  91. Russell SJ, Peng KW. Primer on medical genomics. Part X: Gene therapy. Mayo Clin Proc. 2003 Nov; 78(11):1370-83.
    View PubMed
  92. Peng KW, Frenzke M, Myers R, Soeffker D, Harvey M, Greiner S, Galanis E, Cattaneo R, Federspiel MJ, Russell SJ. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther. 2003 Nov 1; 14(16):1565-77.
    View PubMed
  93. Ma J, Wang C, Peng KW. Electrophoretic deposition of porous hydroxyapatite scaffold. Biomaterials. 2003 Sep; 24(20):3505-10.
    View PubMed
  94. Ma J, Wong HF, Kong LB, Peng KW. Biomimetic processing of nanocrystallite bioactive apatite coating on titanium. Nanotechnology. 2003 Jun; 14(6):619-23.
    View PubMed
  95. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 2003 May 15; 63(10):2462-9.
    View PubMed
  96. Johnson KJ, Peng KW, Allen C, Russell SJ, Galanis E. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction. Gene Ther. 2003 May; 10(9):725-32.
    View PubMed
  97. Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood. 2003 Apr 1; 101(7):2557-62. Epub 2002 Nov 14.
    View PubMed
  98. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002 Aug 15; 62(16):4656-62.
    View PubMed
  99. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med. 2002 May; 8(5):527-31.
    View PubMed
  100. Larochelle A, Peng KW, Russell SJ. Lentiviral vector targeting. Curr Top Microbiol Immunol 2002; 261:143-63
    View PubMed
  101. Peng KW, Pham L, Ye H, Zufferey R, Trono D, Cosset FL, Russell SJ. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther. 2001 Oct; 8(19):1456-63.
    View PubMed
  102. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 2001 Oct 1; 98(7):2002-7.
    View PubMed
  103. Pham L, Ye H, Cosset FL, Russell SJ, Peng KW. Concentration of viral vectors by co-precipitation with calcium phosphate. J Gene Med. 2001 Mar-Apr; 3(2):188-94.
    View PubMed
  104. Randall DJ, Wilson JM, Peng KW, Kok TW, Kuah SS, Chew SF, Lam TJ, Ip YK. The mudskipper, Periophthalmodon schlosseri, actively transports NH4+ against a concentration gradient. Am J Physiol. 1999 Dec; 277(6 Pt 2):R1562-7.
    View PubMed
  105. Peng KW, Russell SJ. Viral vector targeting. Curr Opin Biotechnol. 1999 Oct; 10(5):454-7.
    View PubMed
  106. Peng KW. Strategies for targeting therapeutic gene delivery. Mol Med Today. 1999 Oct; 5(10):448-53.
    View PubMed
  107. Peng KW, Vile R, Cosset FL, Russell S. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther. 1999 Sep; 6(9):1552-7.
    View PubMed
  108. Peng KW, Vile R. Vector development for cancer gene therapy. Tumor Targeting. 1999 Apr; 4(1):3-11.
  109. Peng KW, Vile RG. Vector development for tumor targeting-refining the old and defining the new. Tumor Targeting. 1999; 4:1-9.
  110. Buchholz CJ, Peng KW, Morling FJ, Zhang J, Cosset FL, Russell SJ. In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol. 1998 Oct; 16(10):951-4.
    View PubMed
  111. Peng KW, Morling FJ, Cosset FL, Russell SJ. Retroviral gene delivery system activatable by plasmin. Tumor Targeting. 1998; 3(2):112-120.
  112. Peng KW, Chew SF, Lim CB, Kuah SSL, Kok WL, YK Ip. The mudskipper Periophthalmodon schlosseri and Boleophthalmus boddaerti can tolerate 446 M and 36 M of environmental NH3, respectively. Fish Physiol and Biochem. 1998; 19:59-69.
  113. Morling FJ, Peng KW, Cosset FL, Russell SJ. Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. Virology. 1997 Jul 21; 234(1):51-61.
    View PubMed
  114. Peng KW, Morling FJ, Cosset FL, Murphy G, Russell SJ. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther. 1997 Apr 10; 8(6):729-38.
    View PubMed
  115. Ager S, Nilson BH, Morling FJ, Peng KW, Cosset FL, Russell SJ. Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum Gene Ther. 1996 Nov 10; 7(17):2157-64.
    View PubMed
  116. Ip YK, Peng KW, Chew SF, Lim RWL, Tan GQ. Ammonia production and kinetic properties of glutamate dehydrogenase in the sipunculid Phascolosoma arcuatum exposed to anoxia. Marine Biol. 1994; 119:261-6.
  117. Chew SF, Peng KW, Low WP, Ip YK. Differences in the responses between tissues of the body wall and the internal organs of Phascolosoma arcuatum (Sipuncula) to changes in salinity. Comp Biochem Physiol. 1994; 107A(1):141-7.
  118. Peng KW, Chew SF, Ip YK. Free amino acids and cell volume regulation in the sipunculid. Phascolosoma arcuatum Physiol Zool. 1994; 67(3):580-97.
  119. Peng KW, Ip YK. Is the coelomic plasma of Phascolosoma arcuatum (Sipuncula) hyperosmotic and hypoionic in chloride to the external environment? Zool Sci. 1994; 11:879-82.
  120. Low WP, Peng KW, Phuan SK, Lee CY, Ip YK. A comparative study on the responses of the gills of 2 mudskippers to hypoxia and anoxia. J Comp Physiol B. 1993; 163:487-94.
  121. Ip YK, Chew SF, Peng KW, Lim RWL. Effects of environmental anoxia on concentrations of free amino acids and kinetic properties of glutamate dehydrogenase in three body parts of Phascolosoma arcuatum (Sipuncula). J Exp Mar Biol Ecol. 1992; 165:125-32.